Membrane Potential Mapping with18F-TPP

Starting soon · Phase 1

Conditions studied: Membrane Potential Mapping

In brief

In this study, investigators propose to use PET imaging to study the pharmacokinetics of 18F-TPP and develop methods for imaging membrane potential (ΔΨT) in humans.

Key facts

Study ID

NCT07506616

Run by

Yale University

People needed

24

Starts

2026-06-01

Expected to finish

2033-08-01

Last updated by the study team

2026-05-15

Who can join

Age: 21 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Willing and able to give voluntary written informed consent
• Stated willingness to comply with all study procedures and availability for the duration of the study
• In good general health as evidenced by medical history, physical examination, ECG, serum/urine biochemistry and hematology tests.
• If female of childbearing potential, must agree to use an acceptable method of birth control, as determined by the principal investigator, for the duration of the study.

You may not qualify if…

• Know structural heart disease (e.g. myocardial infarction)
• Abnormal and clinically significant ECG (as determined by the Investigator or his/her designee) at screening.
• Laboratory tests with clinically significant abnormalities at screening
• Pregnancy or Lactation
• MRI incompatible implants (i.e., such as pacemaker, artificial joints, non-removable body piercings) and other contraindications for MRI, such as claustrophobia, having implanted or embedded metal objects/fragments or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked with ferrous metals either as a vocation or hobby (for example, as a sheet metal worker, welder, or machinist).
• Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits followed by the Yale University PET Center.
• Subject who has current, past, or anticipated exposure to radiation in the workplace within one year of the proposed research scans that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits.
• Has any condition that, in the opinion of the investigator, would prevent compliance with the study protocol.
• Arterial Line Exclusion: Blood donation within eight weeks of the start of the study.
• Arterial Line Exclusion: History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto).
• Arterial Line Exclusion: Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) greater than 5msec above the upper limit of normal.
• Arterial Line Exclusion: Unable to safely discontinue or hold aspirin and other NSAID use

Where it is running

• Yale University PET Center — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.